Krystal Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Krystal Biotech, Inc. (KRYS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $280.66 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $275.37, a 56.46% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $176.00, a 12.95% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $155.82, a 90.42% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $81.83, a 30.87% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $168.08, a 0.35% decline from fiscal 2024.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $168.67, a 83.06% increase from fiscal 2023.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $92.14, a 43.65% increase from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $64.14, a 4.10% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $280.66 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $275.37 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $168.08 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $166.80 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $166.90 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $176.00 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | $168.67 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $168.54 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $160.67 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $155.82 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $92.14 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $91.38 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | $88.74 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | $81.83 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $64.14 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $63.03 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $62.19 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $62.53 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $66.88 10-K · filed 2023-02-27 | |||
| 2021-09-30 | $67.15 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $73.42 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $77.46 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $47.29 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $46.46 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $48.10 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $52.28 10-Q · filed 2020-05-04 | |||
| 2019-12-31 | $33.04 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $29.73 10-Q · filed 2019-11-04 | |||
| 2019-06-30 | $27.14 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $23.87 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | $13.79 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $12.90 10-Q · filed 2018-11-05 | |||
| 2018-06-30 | $11.89 10-Q · filed 2018-08-06 | |||
| 2018-03-31 | $9.85 10-Q · filed 2018-05-07 | |||
| 2017-12-31 | $6.22 10-K · filed 2018-03-12 | |||
| 2017-09-30 | $6.22 10-Q · filed 2017-11-13 | |||
| 2016-12-31 | $2.46 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |